Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer.
Anurag M, Jaehnig EJ, Krug K, Lei JT, Bergstrom EJ, Kim BJ, Vashist TD, Huynh AMT, Dou Y, Gou X, Huang C, Shi Z, Wen B, Korchina V, Gibbs RA, Muzny DM, Doddapaneni H, Dobrolecki LE, Rodriguez H, Robles AI, Hiltke T, Lewis MT, Nangia JR, Nemati Shafaee M, Li S, Hagemann IS, Hoog J, Lim B, Osborne CK, Mani DR, Gillette MA, Zhang B, Echeverria GV, Miles G, Rimawi MF, Carr SA, Ademuyiwa FO, Satpathy S, Ellis MJ. Anurag M, et al. Among authors: echeverria gv. Cancer Discov. 2022 Nov 2;12(11):2586-2605. doi: 10.1158/2159-8290.CD-22-0200. Cancer Discov. 2022. PMID: 36001024 Free PMC article.
Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatment.
Baek ML, Lee J, Pendleton KE, Berner MJ, Goff EB, Tan L, Martinez SA, Mahmud I, Wang T, Meyer MD, Lim B, Barrish JP, Porter W, Lorenzi PL, Echeverria GV. Baek ML, et al. Among authors: echeverria gv. Oncogene. 2023 Mar;42(14):1117-1131. doi: 10.1038/s41388-023-02596-8. Epub 2023 Feb 22. Oncogene. 2023. PMID: 36813854 Free PMC article.
Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state.
Echeverria GV, Ge Z, Seth S, Zhang X, Jeter-Jones S, Zhou X, Cai S, Tu Y, McCoy A, Peoples M, Sun Y, Qiu H, Chang Q, Bristow C, Carugo A, Shao J, Ma X, Harris A, Mundi P, Lau R, Ramamoorthy V, Wu Y, Alvarez MJ, Califano A, Moulder SL, Symmans WF, Marszalek JR, Heffernan TP, Chang JT, Piwnica-Worms H. Echeverria GV, et al. Sci Transl Med. 2019 Apr 17;11(488):eaav0936. doi: 10.1126/scitranslmed.aav0936. Sci Transl Med. 2019. PMID: 30996079 Free PMC article.
Improving the odds together: a framework for breast cancer research scientists to include patient advocates in their research.
Stires H, Bado I, Brown T, Carlson M, Chan IS, Echeverria GV, Ewald AJ, Lim B, Lloyd C, Maues J, Oesterreich S, Riter RN, Shanahan K, Welm AL, Newby J. Stires H, et al. Among authors: echeverria gv. NPJ Breast Cancer. 2022 Jun 30;8(1):75. doi: 10.1038/s41523-022-00440-y. NPJ Breast Cancer. 2022. PMID: 35773258 Free PMC article. Review.
Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer.
Echeverria GV, Cai S, Tu Y, Shao J, Powell E, Redwood AB, Jiang Y, McCoy A, Rinkenbaugh AL, Lau R, Trevarton AJ, Fu C, Gould R, Ravenberg EE, Huo L, Candelaria R, Santiago L, Adrada BE, Lane DL, Rauch GM, Yang WT, White JB, Chang JT, Moulder SL, Symmans WF, Hilsenbeck SG, Piwnica-Worms H. Echeverria GV, et al. NPJ Breast Cancer. 2023 Jan 10;9(1):2. doi: 10.1038/s41523-022-00502-1. NPJ Breast Cancer. 2023. PMID: 36627285 Free PMC article.
Evolution of cisplatin resistance through coordinated metabolic reprogramming of the cellular reductive state.
Yu W, Chen Y, Putluri N, Osman A, Coarfa C, Putluri V, Kamal AHM, Asmussen JK, Katsonis P, Myers JN, Lai SY, Lu W, Stephan CC, Powell RT, Johnson FM, Skinner HD, Kazi J, Ahmed KM, Hu L, Threet A, Meyer MD, Bankson JA, Wang T, Davis J, Parker KR, Harris MA, Baek ML, Echeverria GV, Qi X, Wang J, Frederick AI, Walsh AJ, Lichtarge O, Frederick MJ, Sandulache VC. Yu W, et al. Among authors: echeverria gv. Br J Cancer. 2023 Jun;128(11):2013-2024. doi: 10.1038/s41416-023-02253-7. Epub 2023 Apr 3. Br J Cancer. 2023. PMID: 37012319 Free PMC article.
p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer.
Powell E, Shao J, Yuan Y, Chen HC, Cai S, Echeverria GV, Mistry N, Decker KF, Schlosberg C, Do KA, Edwards JR, Liang H, Piwnica-Worms D, Piwnica-Worms H. Powell E, et al. Among authors: echeverria gv. Breast Cancer Res. 2016 Jan 27;18(1):13. doi: 10.1186/s13058-016-0673-9. Breast Cancer Res. 2016. PMID: 26818199 Free PMC article.
Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer.
Powell RT, Redwood A, Liu X, Guo L, Cai S, Zhou X, Tu Y, Zhang X, Qi Y, Jiang Y, Echeverria G, Feng N, Ma X, Giuliani V, Marszalek JR, Heffernan TP, Vellano CP, White JB, Stephan C, Davies PJ, Moulder S, Symmans WF, Chang JT, Piwnica-Worms H. Powell RT, et al. Sci Rep. 2020 Oct 21;10(1):17899. doi: 10.1038/s41598-020-74882-4. Sci Rep. 2020. PMID: 33087803 Free PMC article.
20 results